Analyst Round-Up: Sequenom (SQNM); Numerous Downgrades Following Delay

Following news last night that Sequenom (Nasdaq: SQNM) has delayed the expected launch of its SEQureDx Down syndrome test, and the ensuing 70% drop today, analysts are all over the stock.

Here is a summary of some of the analyst calls:

• downgraded at Cantor Fitzgerald from Buy to Hold. Price target from $42 to $38.
  
• downgraded to Markett Perform at Leerink Swann.
  
• downgraded at Auriga from Buy to Sell with the price target lowered from $20 to $1.
  
• Soleil downgrades from Buy to Hold. Price target cut from $25 to $4.25.
  
• JMP downgrades from Outperform to Market Perform.
  
• downgraded to Underperform at Oppenheimer.

You May Also Be Interested In

• Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
• TD Cowen Reiterates Buy Rating on Broadcom Limited (AVGO), neutral into the print
• B.Riley Starts Weave Communications Inc (WEAV) at Buy